(lp0
S'Albireo Pharma Inc. ALBO  Wall Street Journal - Feb 1, 2001 News Albireo Pharma Inc.ALBO. Significant News Only. 03/14/17; Press Release. Albireo Reports 2016 Financial Results. Press Release.'
p1
aS'Albireo Pharma, Inc.  Lowered to Sell at Zacks Investment Research Chaffey Breeze - 8 hours ago Albireo Pharma, Inc.  was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research note issued to investors on Tuesday.'
p2
aS'BRIEF-Albireo Pharma Inc says filed for mixed shelf offering of up to $100 mln Reuters - Dec 22, 2016 TOKYO, March 21 Asian shares clung to their 15-month highs on Tuesday while the dollar and U.S. bond yields were on the back foot on the prospects of a less-hawkish Federal Reserve policy trajectory.'
p3
aS'Albireo to Present at Upcoming Investor Conferences GlobeNewswire  - 20 hours ago BOSTON, March 28, 2017  -- Albireo Pharma, Inc. , a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will present at the following investor&nbsp;...Latest Stocks: The Zacks: Albireo Pharma, Inc.  Receives Average ... - Petro Global News 24'
p4
aS'ALBIREO PHARMA, INC.  Files An 8-K Departure of Directors or ... Market Exclusive - Jan 27, 2017 On January 23, 2017, the Board of Directors  of Albireo Pharma, Inc. , acting upon the recommendation of the Compensation Committee of the Board , approved an increase in the annual base&nbsp;...'
p5
aS'Boston biotech Albireo goes public in unusual fashion The Boston Globe - Nov 3, 2016 Boston biotech Albireo Pharma Inc. went public Thursday through a reverse merger in which it acquired the stock listing of a Connecticut company, in a deal that will leave Albireo with about $30 million to develop a treatment for a pediatric liver disease.'
p6
aS'Albireo Pharma  Partner Submits NDA for Elobixibat in Japan StreetInsider.com - Feb 1, 2017 Albireo Pharma, Inc.  announced that EA Pharma Co., Ltd. has submitted a New Drug Application  to the Japanese Pharmaceuticals and Medical Devices Agency  for elobixibat for the treatment of chronic constipation in Japan.'
p7
aS'Zacks: Albireo Pharma, Inc.  Receives Average Recommendation of  from ... Chaffey Breeze - Mar 25, 2017 Albireo Pharma logo Shares of Albireo Pharma, Inc.  have received an average broker rating score of 0.00  from the two analysts that provide coverage for the company, Zacks Investment Research reports.'
p8
aS'Latest Stocks: The Brokerages Set $40.00 Price Target for Albireo Pharma, Inc ... Petro Global News 24 - Mar 24, 2017 Albireo Pharma, Inc.  has received an average broker rating score of 0.00  from the two analysts that cover the company, Zacks Investment Research reports.'
p9
aS'Q1 2017 EPS Estimates for Albireo Pharma, Inc. Cut by Analyst  Chaffey Breeze - Mar 19, 2017 Albireo Pharma logo Albireo Pharma, Inc.  - Analysts at William Blair cut their Q1 2017 EPS estimates for shares of Albireo Pharma in a research report issued on Tuesday.'
p10
a.